United States Biotechnology & Medical Research

Exact Sciences Corp (EXAS)

Track

Recent insider trading activity at Exact Sciences Corp has consisted exclusively of planned and proposed sales. The most recent transactions occurred on November 19, 2025, involving executives James Herriott and Jacob A. Orville. These sales follow a series of similar divestments by various officers and directors throughout October and November 2025.

No active insider signal

Not featured in screeners

Featured in screeners

No active insider signal

Not featured in screeners

Ticker: EXAS Exchange: NAS

• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings

Insider activity signal detected

11 activity signals detected for Exact Sciences Corp

Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Exact Sciences Corp. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →

Top insiders

Company data & Insiders

Subscribe to get access to the company description and key fundamental data (market cap, shares outstanding, dividend yield, % of shares held by insiders and more)

Download results Settings

Trades

ORVILLE JACOB A

EVP, GM, Screening

2 sales — total 750,000 USD

Planned sale 19 Nov 2025

Value US$3,457,588.00 | Price 84.18 | Shares 30,956

Proposed sale 19 Nov 2025

Value US$3,957,907.67 | Price 274.58 | Shares 69,540

Herriott James

SVP, General Counsel & Sec

2 sales — total 140,000 USD

Planned sale 19 Nov 2025

Value US$2,118,877.19 | Price 246.76 | Shares 55,929

Proposed sale 19 Nov 2025

Value US$2,465,016.90 | Price 447.78 | Shares 31,729

Baranick Brian

EVP, GM, Precision Oncology

2 sales — total 400,577 USD

Planned sale 4 Nov 2025

Value US$200,288.64 | Price 70.08 | Shares 2,858

Proposed sale 4 Nov 2025

Value US$200,288.64 | Price 70.08 | Shares 2,858

Herriott James

SVP, General Counsel & Sec

2 sales — total 210,240 USD

Planned sale 4 Nov 2025

Value US$105,120.00 | Price 70.08 | Shares 1,500

Proposed sale 4 Nov 2025

Value US$105,120.00 | Price 70.08 | Shares 1,500

Zanotti Katherine S

2 sales — total 1,560,000 USD

Planned sale 24 Oct 2025

Value US$780,000.00 | Price 65.00 | Shares 12,000

Proposed sale 24 Oct 2025

Value US$780,000.00 | Price 65.00 | Shares 12,000

Herriott James

SVP, General Counsel & Sec

2 sales — total 180,000 USD

Planned sale 9 Oct 2025

Value US$90,000.00 | Price 60.00 | Shares 1,500

Proposed sale 9 Oct 2025

Value US$90,000.00 | Price 60.00 | Shares 1,500

Doyle James Edward

2 sales — total 240,000 USD

Planned sale 9 Oct 2025

Value US$120,000.00 | Price 60.00 | Shares 2,000

Proposed sale 9 Oct 2025

Value US$120,000.00 | Price 60.00 | Shares 2,000

Doyle James Edward

2 sales — total 124,799 USD

Planned sale 13 Aug 2025

Value US$62,399.70 | Price 42.02 | Shares 1,485

Proposed sale 13 Aug 2025

Value US$62,399.70 | Price 42.02 | Shares 1,485

Sebelius Kathleen

Former Director

1 sale — total 433,605 USD

Proposed sale 16 Jul 2025

Value US$433,605.12 | Price 53.11 | Shares 8,164

Zanotti Katherine S

2 sales — total 341,225 USD

Planned sale 13 Jun 2025

Value US$170,612.40 | Price 53.20 | Shares 3,207

Proposed sale 13 Jun 2025

Value US$170,612.40 | Price 53.20 | Shares 3,207

Conroy Kevin T

President and CEO

1 purchase — total 1,001,325 USD

Buy 13 Nov 2024

Value US$1,001,325.00 | Price 51.35 | Shares 19,500

Baranick Brian

EVP, GM, Precision Oncology

2 sales — total 130,060 USD

Planned sale 8 Oct 2024

Value US$65,030.00 | Price 70.00 | Shares 929

Proposed sale 8 Oct 2024

Value US$65,030.00 | Price 70.00 | Shares 929

Baranick Brian

EVP, GM, Precision Oncology

2 sales — total 130,060 USD

Planned sale 18 Sep 2024

Value US$65,030.00 | Price 70.00 | Shares 929

Proposed sale 18 Sep 2024

Value US$65,030.00 | Price 70.00 | Shares 929

Conroy Kevin T

President and CEO

3 sales — total 208,419 USD

Planned sale 1 May 2024

Value US$69,473.25 | Price 60.15 | Shares 1,155

Planned sale 1 May 2024

Value US$69,473.25 | Price 60.15 | Shares 1,155

Proposed sale 1 May 2024

Value US$69,472.90 | Price 60.15 | Shares 1,155

Baranick Brian

EVP, GM., Precision Oncology

3 sales — total 19,849 USD

Planned sale 1 May 2024

Value US$6,616.50 | Price 60.15 | Shares 110

Planned sale 1 May 2024

Value US$6,616.50 | Price 60.15 | Shares 110

Proposed sale 1 May 2024

Value US$6,616.47 | Price 60.15 | Shares 110

ORVILLE JACOB A

General Manager, Screening

3 sales — total 18,406 USD

Planned sale 1 May 2024

Value US$6,135.30 | Price 60.15 | Shares 102

Planned sale 1 May 2024

Value US$6,135.30 | Price 60.15 | Shares 102

Proposed sale 1 May 2024

Value US$6,135.27 | Price 60.15 | Shares 102

Elliott Jeffrey Thomas

Chief Financial Officer

3 sales — total 24,541 USD

Planned sale 1 May 2024

Value US$8,180.40 | Price 60.15 | Shares 136

Planned sale 1 May 2024

Value US$8,180.40 | Price 60.15 | Shares 136

Proposed sale 1 May 2024

Value US$8,180.36 | Price 60.15 | Shares 136

Condella Sarah

EVP, Human Resources

2 sales — total 12,271 USD

Planned sale 1 May 2024

Value US$6,135.30 | Price 60.15 | Shares 102

Proposed sale 1 May 2024

Value US$6,135.27 | Price 60.15 | Shares 102

COWARD D SCOTT

2 sales — total 8,060 USD

Planned sale 1 May 2024

Value US$4,030.05 | Price 60.15 | Shares 67

Proposed sale 1 May 2024

Value US$4,030.03 | Price 60.15 | Shares 67

Herriott James

SVP, General Counsel & Sec

2 sales — total 3,609 USD

Planned sale 1 May 2024

Value US$1,804.50 | Price 60.15 | Shares 30

Proposed sale 1 May 2024

Value US$1,804.49 | Price 60.15 | Shares 30

Cunningham Everett

Chief Commercial Officer

2 sales — total 16,361 USD

Planned sale 1 May 2024

Value US$8,180.40 | Price 60.15 | Shares 136

Proposed sale 1 May 2024

Value US$8,180.36 | Price 60.15 | Shares 136

Baranick Brian

EVP, GM., Precision Oncology

2 sales — total 146,787 USD

Planned sale 2 Apr 2024

Value US$73,393.32 | Price 79.43 | Shares 924

Proposed sale 2 Apr 2024

Value US$73,393.32 | Price 79.43 | Shares 924

Condella Sarah

EVP, Human Resources

2 sales — total 280,000 USD

Planned sale 1 Apr 2024

Value US$140,000.00 | Price 70.00 | Shares 2,000

Proposed sale 1 Apr 2024

Value US$140,000.00 | Price 70.00 | Shares 2,000

Condella Sarah

EVP, Human Resources

2 sales — total 280,000 USD

Planned sale 28 Mar 2024

Value US$140,000.00 | Price 70.00 | Shares 2,000

Proposed sale 28 Mar 2024

Value US$140,000.00 | Price 70.00 | Shares 2,000

ORVILLE JACOB A

General Manager, Screening

2 sales — total 255,549 USD

Planned sale 1 Mar 2024

Value US$127,775.28 | Price 59.32 | Shares 2,154

Proposed sale 1 Mar 2024

Value US$127,773.34 | Price 59.32 | Shares 2,154

Herriott James

General Counsel

2 sales — total 102,267 USD

Planned sale 1 Mar 2024

Value US$51,133.84 | Price 59.32 | Shares 862

Proposed sale 1 Mar 2024

Value US$51,133.06 | Price 59.32 | Shares 862

Conroy Kevin T

President and CEO

2 sales — total 981,264 USD

Planned sale 1 Mar 2024

Value US$490,635.72 | Price 59.32 | Shares 8,271

Proposed sale 1 Mar 2024

Value US$490,628.28 | Price 59.32 | Shares 8,271

Elliott Jeffrey Thomas

Chief Financial Officer

2 sales — total 286,158 USD

Planned sale 1 Mar 2024

Value US$143,079.84 | Price 59.32 | Shares 2,412

Proposed sale 1 Mar 2024

Value US$143,077.67 | Price 59.32 | Shares 2,412

Cunningham Everett

Chief Commercial Officer

2 sales — total 286,158 USD

Planned sale 1 Mar 2024

Value US$143,079.84 | Price 59.32 | Shares 2,412

Proposed sale 1 Mar 2024

Value US$143,077.67 | Price 59.32 | Shares 2,412

Doyle James Edward

2 sales — total 230,000 USD

Planned sale 1 Mar 2024

Value US$115,000.00 | Price 57.50 | Shares 2,000

Proposed sale 1 Mar 2024

Value US$115,000.00 | Price 57.50 | Shares 2,000

Baranick Brian

Gen. Mgr., Precision Oncology

2 sales — total 275,599 USD

Planned sale 1 Mar 2024

Value US$137,800.36 | Price 59.32 | Shares 2,323

Proposed sale 1 Mar 2024

Value US$137,798.27 | Price 59.32 | Shares 2,323

LEVANGIE DANIEL J

2 sales — total 575,000 USD

Planned sale 1 Mar 2024

Value US$287,500.00 | Price 57.50 | Shares 5,000

Proposed sale 1 Mar 2024

Value US$287,500.00 | Price 57.50 | Shares 5,000

Condella Sarah

EVP, Human Resources

2 sales — total 204,534 USD

Planned sale 1 Mar 2024

Value US$102,267.68 | Price 59.32 | Shares 1,724

Proposed sale 1 Mar 2024

Value US$102,266.13 | Price 59.32 | Shares 1,724

Condella Sarah

EVP, Human Resources

1 sale — total 106,953 USD

Planned sale 27 Feb 2024

Value US$106,953.20 | Price 56.89 | Shares 1,880

ORVILLE JACOB A

General Manager, Screening

1 sale — total 106,896 USD

Planned sale 27 Feb 2024

Value US$106,896.31 | Price 56.89 | Shares 1,879

Baranick Brian

Gen. Mgr., Precision Oncology

1 sale — total 115,316 USD

Planned sale 27 Feb 2024

Value US$115,316.03 | Price 56.89 | Shares 2,027

Herriott James

General Counsel

1 sale — total 44,602 USD

Planned sale 27 Feb 2024

Value US$44,601.76 | Price 56.89 | Shares 784

Conroy Kevin T

President and CEO

1 sale — total 356,302 USD

Planned sale 27 Feb 2024

Value US$356,302.07 | Price 56.89 | Shares 6,263

Cunningham Everett

Chief Commercial Officer

1 sale — total 207,535 USD

Planned sale 27 Feb 2024

Value US$207,534.72 | Price 56.89 | Shares 3,648

Elliott Jeffrey Thomas

Chief Financial Officer

1 sale — total 154,172 USD

Planned sale 27 Feb 2024

Value US$154,171.90 | Price 56.89 | Shares 2,710

Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other

Notification date	Transaction date	B/S Transaction type	Insider and/or position	Nb. shares Price Value	Number of shares	Price	Value
2025-11-21	2025-11-19	PlS Planned sale	ORVILLE JACOB A EVP, GM, Screening Officer	30,956 -7.1% 84.18 US$3,457,588	30,956 -7.1%	84.18	US$3,457,588
2025-11-21	2025-11-19	PlS Planned sale	Herriott James SVP, General Counsel & Sec Officer	55,929 -16.0% 246.76 US$2,118,877	55,929 -16.0%	246.76	US$2,118,877
2025-11-19	2025-11-19	PrS Proposed sale	ORVILLE JACOB A Officer Officer	69,540 274.58 US$3,957,908	69,540	274.58	US$3,957,908
2025-11-19	2025-11-19	PrS Proposed sale	Herriott James Officer Officer	1,000 70.00 US$70,000	1,000	70.00	US$70,000
2025-11-06	2025-11-04	PlS Planned sale	Baranick Brian EVP, GM, Precision Oncology Officer	2,858 -11.3% 70.08 US$200,289	2,858 -11.3%	70.08	US$200,289
2025-11-06	2025-11-04	PlS Planned sale	Herriott James SVP, General Counsel & Sec Officer	1,500 -10.6% 70.08 US$105,120	1,500 -10.6%	70.08	US$105,120
2025-11-04	2025-11-04	PrS Proposed sale	Baranick Brian Officer Officer	2,858 70.08 US$200,289	2,858	70.08	US$200,289
2025-11-04	2025-11-04	PrS Proposed sale	Herriott James Officer Officer	1,500 70.08 US$105,120	1,500	70.08	US$105,120
2025-10-27	2025-10-24	PlS Planned sale	3.8 Zanotti Katherine S Non-Executive Director	12,000 -16.5% 65.00 US$780,000	12,000 -16.5%	65.00	US$780,000
2025-10-24	2025-10-24	PrS Proposed sale	3.8 Zanotti Katherine S Director Non-Executive Director	12,000 65.00 US$780,000	12,000	65.00	US$780,000
2025-10-10	2025-10-09	PlS Planned sale	Herriott James SVP, General Counsel & Sec Officer	1,500 -9.6% 60.00 US$90,000	1,500 -9.6%	60.00	US$90,000
2025-10-10	2025-10-09	PlS Planned sale	Doyle James Edward Non-Executive Director	2,000 -3.3% 60.00 US$120,000	2,000 -3.3%	60.00	US$120,000
2025-10-09	2025-10-09	PrS Proposed sale	Herriott James Officer Officer	1,500 60.00 US$90,000	1,500	60.00	US$90,000
2025-10-09	2025-10-09	PrS Proposed sale	Doyle James Edward Director Non-Executive Director	2,000 60.00 US$120,000	2,000	60.00	US$120,000
2025-08-14	2025-08-13	PlS Planned sale	Doyle James Edward Non-Executive Director	1,485 -2.4% 42.02 US$62,400	1,485 -2.4%	42.02	US$62,400
2025-08-13	2025-08-13	PrS Proposed sale	Doyle James Edward Director Non-Executive Director	1,485 42.02 US$62,400	1,485	42.02	US$62,400
2025-07-16	2025-07-16	PrS Proposed sale	3.1 Sebelius Kathleen Former Director Non-Executive Director	8,164 53.11 US$433,605	8,164	53.11	US$433,605
2025-06-16	2025-06-13	PlS Planned sale	3.8 Zanotti Katherine S Non-Executive Director	3,207 -4.2% 53.20 US$170,612	3,207 -4.2%	53.20	US$170,612
2025-06-13	2025-06-13	PrS Proposed sale	3.8 Zanotti Katherine S Director Non-Executive Director	3,207 53.20 US$170,612	3,207	53.20	US$170,612
2024-11-13	2024-11-13	B Purchase	1.8 Conroy Kevin T President and CEO Executive Director	19,500 +1.8% 51.35 US$1,001,325	19,500 +1.8%	51.35	US$1,001,325
2024-10-09	2024-10-08	PlS Planned sale	Baranick Brian EVP, GM, Precision Oncology Officer	929 -6.8% 70.00 US$65,030	929 -6.8%	70.00	US$65,030
2024-10-08	2024-10-08	PrS Proposed sale	Baranick Brian Officer Officer	929 70.00 US$65,030	929	70.00	US$65,030
2024-09-19	2024-09-18	PlS Planned sale	Baranick Brian EVP, GM, Precision Oncology Officer	929 -6.4% 70.00 US$65,030	929 -6.4%	70.00	US$65,030
2024-09-18	2024-09-18	PrS Proposed sale	Baranick Brian Officer Officer	929 70.00 US$65,030	929	70.00	US$65,030
2024-05-02	2024-05-01	PlS Planned sale	1.8 Conroy Kevin T President and CEO Executive Director	1,155 -0.1% 60.15 US$69,473	1,155 -0.1%	60.15	US$69,473
2024-05-02	2024-05-01	PlS Planned sale	1.8 Conroy Kevin T President and CEO Executive Director	1,155 -0.1% 60.15 US$69,473	1,155 -0.1%	60.15	US$69,473
2024-05-02	2024-05-01	PlS Planned sale	Baranick Brian EVP, GM., Precision Oncology Officer	110 -0.8% 60.15 US$6,616	110 -0.8%	60.15	US$6,616
2024-05-02	2024-05-01	PlS Planned sale	Baranick Brian EVP, GM., Precision Oncology Officer	110 -0.8% 60.15 US$6,616	110 -0.8%	60.15	US$6,616
2024-05-02	2024-05-01	PlS Planned sale	ORVILLE JACOB A General Manager, Screening Officer	102 -0.7% 60.15 US$6,135	102 -0.7%	60.15	US$6,135
2024-05-02	2024-05-01	PlS Planned sale	ORVILLE JACOB A General Manager, Screening Officer	102 -0.7% 60.15 US$6,135	102 -0.7%	60.15	US$6,135
2024-05-02	2024-05-01	PlS Planned sale	1.5 Elliott Jeffrey Thomas Chief Financial Officer Officer	136 -1.1% 60.15 US$8,180	136 -1.1%	60.15	US$8,180
2024-05-02	2024-05-01	PlS Planned sale	1.5 Elliott Jeffrey Thomas Chief Financial Officer Officer	136 -1.1% 60.15 US$8,180	136 -1.1%	60.15	US$8,180
2024-05-02	2024-05-01	PlS Planned sale	3.0 Condella Sarah EVP, Human Resources Officer	102 -0.1% 60.15 US$6,135	102 -0.1%	60.15	US$6,135
2024-05-02	2024-05-01	PlS Planned sale	COWARD D SCOTT Non-Executive Director	67 -0.1% 60.15 US$4,030	67 -0.1%	60.15	US$4,030
2024-05-02	2024-05-01	PlS Planned sale	Herriott James SVP, General Counsel & Sec Officer	30 -0.3% 60.15 US$1,804	30 -0.3%	60.15	US$1,804
2024-05-02	2024-05-01	PlS Planned sale	2.9 Cunningham Everett Chief Commercial Officer Officer	136 -0.3% 60.15 US$8,180	136 -0.3%	60.15	US$8,180
2024-05-01	2024-05-01	PrS Proposed sale	1.5 Elliott Jeffrey Thomas Officer Officer	136 60.15 US$8,180	136	60.15	US$8,180
2024-05-01	2024-05-01	PrS Proposed sale	COWARD D SCOTT Director Non-Executive Director	67 60.15 US$4,030	67	60.15	US$4,030
2024-05-01	2024-05-01	PrS Proposed sale	2.9 Cunningham Everett Officer Officer	136 60.15 US$8,180	136	60.15	US$8,180
2024-05-01	2024-05-01	PrS Proposed sale	3.0 Condella Sarah Officer Officer	102 60.15 US$6,135	102	60.15	US$6,135
2024-05-01	2024-05-01	PrS Proposed sale	1.8 Conroy Kevin T Officer; Director Executive Director	1,155 60.15 US$69,473	1,155	60.15	US$69,473
2024-05-01	2024-05-01	PrS Proposed sale	ORVILLE JACOB A Officer Officer	102 60.15 US$6,135	102	60.15	US$6,135
2024-05-01	2024-05-01	PrS Proposed sale	Baranick Brian Officer Officer	110 60.15 US$6,616	110	60.15	US$6,616
2024-05-01	2024-05-01	PrS Proposed sale	Herriott James Officer Officer	30 60.15 US$1,804	30	60.15	US$1,804
2024-04-03	2024-04-02	PlS Planned sale	Baranick Brian EVP, GM., Precision Oncology Officer	924 -6.6% 79.43 US$73,393	924 -6.6%	79.43	US$73,393
2024-04-02	2024-04-02	PrS Proposed sale	Baranick Brian Officer Officer	924 79.43 US$73,393	924	79.43	US$73,393
2024-04-03	2024-04-01	PlS Planned sale	3.0 Condella Sarah EVP, Human Resources Officer	2,000 -2.7% 70.00 US$140,000	2,000 -2.7%	70.00	US$140,000
2024-04-01	2024-04-01	PrS Proposed sale	3.0 Condella Sarah Officer Officer	2,000 70.00 US$140,000	2,000	70.00	US$140,000
2024-04-01	2024-03-28	PlS Planned sale	3.0 Condella Sarah EVP, Human Resources Officer	2,000 -2.6% 70.00 US$140,000	2,000 -2.6%	70.00	US$140,000
2024-03-28	2024-03-28	PrS Proposed sale	3.0 Condella Sarah Officer Officer	2,000 70.00 US$140,000	2,000	70.00	US$140,000
2024-03-04	2024-03-01	PlS Planned sale	ORVILLE JACOB A General Manager, Screening Officer	2,154 -13.1% 59.32 US$127,775	2,154 -13.1%	59.32	US$127,775
2024-03-04	2024-03-01	PlS Planned sale	Herriott James General Counsel Officer	862 -8.6% 59.32 US$51,134	862 -8.6%	59.32	US$51,134
2024-03-04	2024-03-01	PlS Planned sale	1.8 Conroy Kevin T President and CEO Executive Director	8,271 -0.6% 59.32 US$490,636	8,271 -0.6%	59.32	US$490,636
2024-03-04	2024-03-01	PlS Planned sale	1.5 Elliott Jeffrey Thomas Chief Financial Officer Officer	2,412 -18.1% 59.32 US$143,080	2,412 -18.1%	59.32	US$143,080
2024-03-04	2024-03-01	PlS Planned sale	2.9 Cunningham Everett Chief Commercial Officer Officer	2,412 -5.0% 59.32 US$143,080	2,412 -5.0%	59.32	US$143,080
2024-03-04	2024-03-01	PlS Planned sale	Doyle James Edward Non-Executive Director	2,000 -3.8% 57.50 US$115,000	2,000 -3.8%	57.50	US$115,000
2024-03-04	2024-03-01	PlS Planned sale	Baranick Brian Gen. Mgr., Precision Oncology Officer	2,323 -14.1% 59.32 US$137,800	2,323 -14.1%	59.32	US$137,800
2024-03-04	2024-03-01	PlS Planned sale	LEVANGIE DANIEL J Non-Executive Director	5,000 -17.9% 57.50 US$287,500	5,000 -17.9%	57.50	US$287,500
2024-03-04	2024-03-01	PlS Planned sale	3.0 Condella Sarah EVP, Human Resources Officer	1,724 -2.2% 59.32 US$102,268	1,724 -2.2%	59.32	US$102,268
2024-03-01	2024-03-01	PrS Proposed sale	2.9 Cunningham Everett Officer Officer	2,412 59.32 US$143,078	2,412	59.32	US$143,078
2024-03-01	2024-03-01	PrS Proposed sale	Herriott James Officer Officer	862 59.32 US$51,133	862	59.32	US$51,133
2024-03-01	2024-03-01	PrS Proposed sale	3.0 Condella Sarah Officer Officer	1,724 59.32 US$102,266	1,724	59.32	US$102,266
2024-03-01	2024-03-01	PrS Proposed sale	1.5 Elliott Jeffrey Thomas Officer Officer	2,412 59.32 US$143,078	2,412	59.32	US$143,078
2024-03-01	2024-03-01	PrS Proposed sale	ORVILLE JACOB A Officer Officer	2,154 59.32 US$127,773	2,154	59.32	US$127,773
2024-03-01	2024-03-01	PrS Proposed sale	Baranick Brian Officer Officer	2,323 59.32 US$137,798	2,323	59.32	US$137,798
2024-03-01	2024-03-01	PrS Proposed sale	1.8 Conroy Kevin T Officer; Director Executive Director	8,271 59.32 US$490,628	8,271	59.32	US$490,628
2024-03-01	2024-03-01	PrS Proposed sale	Doyle James Edward Director Non-Executive Director	2,000 57.50 US$115,000	2,000	57.50	US$115,000
2024-03-01	2024-03-01	PrS Proposed sale	LEVANGIE DANIEL J Director Non-Executive Director	5,000 57.50 US$287,500	5,000	57.50	US$287,500
2024-02-28	2024-02-27	PlS Planned sale	3.0 Condella Sarah EVP, Human Resources Officer	1,880 -2.5% 56.89 US$106,953	1,880 -2.5%	56.89	US$106,953
2024-02-28	2024-02-27	PlS Planned sale	ORVILLE JACOB A General Manager, Screening Officer	1,879 -13.8% 56.89 US$106,896	1,879 -13.8%	56.89	US$106,896
2024-02-28	2024-02-27	PlS Planned sale	Baranick Brian Gen. Mgr., Precision Oncology Officer	2,027 -14.8% 56.89 US$115,316	2,027 -14.8%	56.89	US$115,316
2024-02-28	2024-02-27	PlS Planned sale	Herriott James General Counsel Officer	784 -8.8% 56.89 US$44,602	784 -8.8%	56.89	US$44,602
2024-02-28	2024-02-27	PlS Planned sale	1.8 Conroy Kevin T President and CEO Executive Director	6,263 -0.5% 56.89 US$356,302	6,263 -0.5%	56.89	US$356,302
2024-02-28	2024-02-27	PlS Planned sale	2.9 Cunningham Everett Chief Commercial Officer Officer	3,648 -7.8% 56.89 US$207,535	3,648 -7.8%	56.89	US$207,535
2024-02-28	2024-02-27	PlS Planned sale	1.5 Elliott Jeffrey Thomas Chief Financial Officer Officer	2,710 -25.2% 56.89 US$154,172	2,710 -25.2%	56.89	US$154,172

Explore more

More insider trading research around Exact Sciences Corp

More insider trades in United States

Similar Healthcare companies with insider activity

More Pharmaceuticals & Medical Research companies with insider activity

More Biotechnology & Medical Research companies with insider activity

Insider trading in North America

Exact Sciences Corp (EXAS)

Track

Featured in screeners

Upgrade for signal details

Transactions

Insider

Sort by

Trades

Explore more